Woojin B&G Presents Swine Influenza Vaccine Achievements at ASV 2025

Woojin B&G, a company specializing in veterinary pharmaceuticals, has been recognized for its research achievements in developing a swine influenza vaccine at an international virology conference.

Woojin B&G announced on July 29 that it unveiled the results of its collaborative research on swine influenza vaccine development, conducted jointly with the College of Veterinary Medicine at Jeonbuk National University and the School of Medicine at Kyungpook National University, at the 'ASV (American Society for Virology) 2025' international academic conference held in Montreal, Canada.

ASV is a professional society where virus researchers from around the world gather annually to discuss the latest research findings, as well as vaccine and therapeutic strategies.

This presentation detailed the completion of a nationwide disease surveillance project and in-depth analysis of various influenza A viruses (swIAV) currently circulating in domestic swine farms. Through this, the process of selecting and testing multivalent vaccine candidates?capable of simultaneously inducing immune responses against multiple pathogens and posing a high risk of human infection?was introduced.

This research was supported by the Ministry of Science and ICT's Bio and Medical Technology Development Program. Under the leadership of the Woojin B&G Vaccine Research Institute, a comprehensive analysis was conducted through close collaboration with Jeonbuk National University, Kyungpook National University, the Institute for Basic Science (IBS), and the Korea Research Institute of Veterinary Biologics (KRIVB), covering vaccine candidate evaluation, pathogenicity testing, and verification of genetic diversity. In particular, joint research with a domestic immunotherapeutic specialist company is also underway to explore the applicability of new immunostimulants.

The research team conducted a comprehensive evaluation of various scientifically validated indicators for major swine influenza virus genotypes (H1N1, H1N2, H3N2, etc.) isolated in Korea. Three multivalent vaccine candidates, which offer broad cross-protection and match circulating field strains with a high risk of human infection, were ultimately selected. Various experiments are currently ongoing as a result.

During this process, titer measurement and antibody analysis technologies developed independently by each research institution, which quantitatively assess vaccine efficacy, served as a crucial foundation. To overcome the antigen mismatch problem of commercial vaccines, a rational vaccine strain selection system based on integrated genetic-antigen-pathogenicity data was applied.

All results presented at this conference will be used as domestic vaccine approval data for future commercialization.

A representative from the Woojin B&G Vaccine Research Institute stated, "This presentation marks the first official sharing of a scientifically grounded approach to swine influenza vaccine development with the international virology community, based on data accumulated by our institute, Jeonbuk National University, Kyungpook National University, and other domestic research organizations. We will continue to focus on developing field-oriented vaccines that can provide practical solutions for swine diseases in Korea."

Meanwhile, Woojin B&G has been continuously developing domestic vaccines for major diseases such as porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus (PCV2), and classical swine fever virus (CSFV). Through this announcement, the company has also established its next-generation vaccine competitiveness in the swine influenza virus field on an international level.